BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
ZIIHERA (zanidatamab-hrii) by Jazz Pharmaceuticals is her2-directed antibody interactions [moa]. Approved for bispecific her2-directed antibody [epc]. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIIHERA (zanidatamab-hrii) is a bispecific HER2-directed antibody approved by the FDA on November 20, 2024, for treating HER2-positive cancers. It works by simultaneously engaging two distinct HER2 epitopes, enabling dual mechanism engagement including immune cell recruitment and HER2 signal inhibition. The drug represents a novel approach to HER2-targeted therapy beyond traditional monoclonal antibodies.
Growth
As a newly approved growth-stage bispecific, ZIIHERA is building commercial infrastructure with moderate competitive pressure (30% index), creating near-term hiring demand across field teams and market access roles.
Mechanism of Action
HER2-directed Antibody Interactions
Pharmacologic Class:
Bispecific HER2-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Jazz Pharmaceuticals is hiring 6 roles related to this product
Worked on ZIIHERA at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.